Related Experiment Video
Updated: Aug 12, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
A review of carvedilol arrhythmia data in clinical trials
1Division of Cardiovascular Diseases, Main Line Health Heart Center, Wynnewood, PA, Philadelphia, PA 19096, USA. koweypr@mlhheart.org
Insights
Carvedilol effectively controls atrial fibrillation and reduces mortality in heart failure and post-myocardial infarction patients. This beta-blocker also lowers the risk of ventricular arrhythmias and sudden cardiac death.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Beta-blockers are investigated for antiarrhythmic properties.
- Not all beta-blockers demonstrate equal efficacy in clinical trials.
- Carvedilol, a third-generation beta-blocker, shows promise as an antiarrhythmic agent.
Purpose of the Study:
- To review clinical arrhythmia data for carvedilol.
- To evaluate carvedilol's effectiveness in various cardiac conditions.
- To assess its role in managing arrhythmias and sudden death.
Main Methods:
- Review of large-scale clinical trials and smaller studies on carvedilol.
- Analysis of data concerning atrial fibrillation and ventricular arrhythmias.
- Evaluation of mortality benefits in heart failure and post-myocardial infarction patients.
Main Results:
- Carvedilol serves as effective adjunctive rate-control therapy for atrial fibrillation.
- It prevents mortality in heart failure and post-MI patients with left ventricular dysfunction.
- Carvedilol reduces the incidence of ventricular arrhythmias and sudden death.
Conclusions:
- Carvedilol demonstrates significant antiarrhythmic and mortality-reducing benefits.
- Its efficacy extends to patients with and without atrial fibrillation.
- Carvedilol is a valuable therapeutic option in managing complex cardiac conditions.
Abstract:
beta-Blockers are currently being evaluated more intensively to define their role in clinical use as antiarrhythmic agents. beta-Adrenergic blockade has been studied in relation to atrial fibrillation, ventricular arrhythmias, and sudden death; however, it is apparent from a number of studies that not all beta-blockers are equally effective. Randomized clinical trial data, both in heart failure and post-myocardial infarction (MI) patients, have shown differences in mortality benefits in addition to a variable effect on arrhythmias and sudden death. Carvedilol, a third-generation beta-blocker with proven clinical benefit in the management of heart failure and post-MI patients, has properties that may make it an effective antiarrhythmic agent. This paper reviews the current clinical arrhythmia data available for carvedilol from large-scale clinical trials and small studies. The trial evidence demonstrates that carvedilol therapy can be an effective adjunctive rate-control therapy in patients with atrial fibrillation, prevent mortality in patients with heart failure or post-MI with left ventricular dysfunction, with or without atrial fibrillation, and reduce its onset and the incidence of ventricular arrhythmia and sudden death.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias IV: Characteristics of Bradyarrhythmias

